Oral ribupatide
KAI-9531 · HRS9531 · Ribupatide · Kailera Therapeutics
Once-daily oral ribupatide is in Phase 3 in China. The global Phase 3 program is planned for the first half of 2027.
Selected study results
China oral ribupatide Phase 2Mean body-weight changeBody weight decreased 12.1% · 26 weeks · Phase 2
Mean body-weight change · 26 weeks
Study focus: Weight management
Up to 12.1% mean weight loss with oral ribupatide in the 26-week Phase 2 study.
Adults with obesity in China · 25 mg or 50 mg once daily · N not included in this summary · Efficacy estimand; sponsor-reported conference data. Results & methods ↗
Sponsor summary does not provide the comparator-arm estimate in this update. Vomiting was reported in 11.4% and 7.5% at 25 mg and 50 mg, respectively.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Safety context
Sponsor-reported vomiting occurred in 11.4% at 25 mg and 7.5% at 50 mg in the China Phase 2 oral study.
Mechanism at a glance
Obesity stage by formulation
Latest: China Phase 2 reported up to 12.1% mean weight loss at Week 26. The separate China Phase 3 tablet study started July 24, 2026.
Next: Global Phase 3 obesity trials planned for the first half of 2027.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies1 record
HRS9531 tablets · China Phase 3
Weight managementPlacebo-controlled study of oral HRS9531 in an estimated 675 adults with overweight or obesity. Week-52 primary endpoints are percentage weight change and the proportion achieving at least 5% weight loss.
Phase 2 studies1 record
China oral ribupatide Phase 2
Weight managementAdults with obesity; 25 mg and 50 mg oral doses, 26 weeks.
